Combination treatment for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new combination of two investigational drugs for people with advanced solid tumors, especially lung cancers. The goal is to see if the combination can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a type of cancer that has spread and cannot be cured by surgery (advanced or metastatic).
- You must have either small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC) that is squamous or non-squamous.
- You must have at least one tumor that can be measured by scans.
- You must not have active lung disease like interstitial lung disease or uncontrolled asthma/COPD.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (GSK5764227) for people whose extensive-stage small cell lung cancer has gotten worse after platinum chemotherapy combined with immunotherapy. The goal is to see if this targeted treatment can help shrink tumors and control the cancer.
This trial tests new drug combinations for people with advanced or metastatic non-small cell lung cancer (NSCLC). Depending on your PD-L1 level and genetic profile, you may be placed in one of three groups to see if these combinations help shrink or control your tumor.
This trial tests a new combination of three medicines (two chemotherapies and an immunotherapy) for people with a certain type of advanced lung cancer called squamous non-small cell lung cancer. The goal is to see if this combo can help shrink or control the cancer better than current treatments.
This trial tests a new combination of two drugs for people with extensive-stage small cell lung cancer that has progressed after initial treatment. The goal is to see if this combination can help control the cancer.
This trial tests a new drug (EVM14) combined with an existing immunotherapy called ivonescimab for people with advanced squamous lung cancer that has not been treated before. The goal is to see if the combination is safe and if it helps shrink tumors.
This study is testing a new combination of two immunotherapy drugs (ivonescimab and cadonilimab) plus standard chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this combination can be more effective than current treatments.
Hear when a new Neoplasms, Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.